MedaSystems, a Menlo Park, CA-based SaaS platform for expanded access and investigator-initiated studies, has secured additional funding.
Investors
Existing investors, including the Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems, participated in the round.
MedaSystems Use of Funds
The company will use the fresh funds to advance its AI-driven workflow platform.
About MedaSystems
MedaSystems is a developer of software designed to manage requests for experimental therapies, supporting expanded access, post-trial access, and investigator-initiated studies. Its SaaS platform automate workflows, manage treatment inquiries, improve patient access, and collect real-world data. The platform provides a centralized hub for healthcare providers, pharmaceutical companies, and regulatory partners to collaborate seamlessly.
Funding Details
Company: MedaSystems, Inc.
Raised: Undisclosed
Round: Seed
Funding Date: March 2025
Investors: Debiopharm Innovation Fund, Nina Capital, Young Sohn
Company Website: https://medasystems.com/
Software Category: Expanded Access and AI Workflow
Source: https://www.businesswire.com/news/home/20250305289858/en/